Cancer treatment firm US Oncology of Houston has released preliminary fiscal 2005 third-quarter results.
The company said that for the period (end-September 30) it anticipates revenues between $640 million to $650 million and net income of $9.5 million to $11 million.
US Oncology has increased its prior guidance on full-year results to reflect higher anticipated adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the fiscal year of approximately $230 million to $235 million. This excludes the impact of a $14.5 million compensation expense relating to a long-term incentive plan incurred during the first quarter of this year, the company said.
By AuntMinnie.com staff writers
October 26, 2005
Related Reading
US Oncology names Broussard as president, October 21, 2005
Kodak inks US Oncology deal, October 13, 2005
US Oncology completes buyout, August 23, 2004
US Oncology shows strong Q1, April 30, 2004
US Oncology planned merger draws lawsuits, March 25, 2004
Copyright © 2005 AuntMinnie.com
